Amorfix makes R&D appointment
This article was originally published in Scrip
Amorfix Life Sciences, a Canadian theranostics company developing products and diagnostics for misfolded proteins in brain-wasting diseases and cancer, has appointed Dr Robert Gundel vice-president of R&D. He has 25 years' experience in the industry, having worked at Boehringer Ingelheim, Bayer and Arius Research (Roche). Before taking his role with Amorfix, Dr Gundel served as chief scientific officer at Heat Biologics, and before that was vice-president and head of research at Elusys Therapeutics. Last week, Amorfix announced that it was in discussions with potential partners to further develop its amyloid lateral sclerosis programme, which includes antibodies and vaccines for misfolded SOD1 (copper-zinc superocide dismutase), which it has identified, co-located with beta-amyloid, in the brains of patients with Alzheimer's disease (scripnews.com, January 4th, 2010).